J
Julien Fourcade
Researcher at University of Pittsburgh
Publications - 20
Citations - 2785
Julien Fourcade is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Cytotoxic T cell & T cell. The author has an hindex of 12, co-authored 20 publications receiving 2363 citations.
Papers
More filters
Journal ArticleDOI
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade,Zhaojun Sun,Mourad Benallaoua,Philippe Guillaume,Immanuel F. Luescher,Cindy Sander,John M. Kirkwood,Vijay K. Kuchroo,Hassane M. Zarour +8 more
TL;DR: These findings support the use of Tim-3–Tim-3L blockade together with PD-1–PD-L1 blockade to reverse tumor-induced T cell exhaustion/dysfunction in patients with advanced melanoma.
Journal ArticleDOI
TIGIT and PD-1 impair tumor antigen–specific CD8 + T cells in melanoma patients
Joe-Marc Chauvin,Ornella Pagliano,Julien Fourcade,Zhaojun Sun,Hong Wang,Cindy Sander,John M. Kirkwood,Tseng-hui Timothy Chen,Mark Maurer,Alan J. Korman,Hassane M. Zarour +10 more
TL;DR: The results show that TIGIT and PD-1 regulate the expansion and function of TA-specific CD8⁺ T cells and CD8¹ TILs in melanoma patients and suggest that dual TIGit andPD-1 blockade should be further explored to elicit potent antitumor CD8 ™ T cell responses in patients with advanced melanoma.
Journal ArticleDOI
CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
Julien Fourcade,Zhaojun Sun,Ornella Pagliano,Philippe Guillaume,Immanuel F. Luescher,Cindy Sander,John M. Kirkwood,Daniel Olive,Vijay K. Kuchroo,Hassane M. Zarour +9 more
TL;DR: These findings indicate that targeting BTLA along with the PD-1 and Tim-3 pathways is critical to reverse an important mechanism of immune escape in patients with advanced melanoma.
Journal ArticleDOI
PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines
Julien Fourcade,Zhaojun Sun,Ornella Pagliano,Joe Marc Chauvin,Cindy Sander,Bratislav Janjic,Ahmad A. Tarhini,Hussein Tawbi,John M. Kirkwood,Stergios J. Moschos,Hong Wang,Philippe Guillaume,Immanuel F. Luescher,Arthur M. Krieg,Ana C. Anderson,Vijay K. Kuchroo,Hassane M. Zarour +16 more
TL;DR: These findings support the use of PD-1 and Tim-3 blockades with cancer vaccines to stimulate potent antitumor T-cell responses and increase the likelihood of clinical responses in patients with advanced melanoma.
Journal ArticleDOI
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Julien Fourcade,Pavol Kudela,Zhaojun Sun,Hongmei Shen,Stephanie R. Land,Diana Lenzner,Philippe Guillaume,Immanuel F. Luescher,Cindy Sander,Soldano Ferrone,John M. Kirkwood,Hassane M. Zarour +11 more
TL;DR: The findings support the role of PD-1 as a regulator of NY-ESO-1-specific CD8+ T cell expansion in the context of chronic Ag stimulation and support the use ofPD-1/PD-L1 pathway blockade in cancer patients to partially restore NY- ESO- 1-specific T cell numbers and functions, increasing the likelihood of tumor regression.